Amgen Expands Development Plans For Highly Anticipated Obesity Drug Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors.
Where Will Viking Therapeutics Be in 3 Years? Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
